exist
strategi
treatment
diseas
focus
deliveri
nake
molecul
therapeut
activ
chemic
synthes
molecul
recombin
protein
produc
divers
platform
bacteria
yeast
insect
cell
mammalian
cell
among
other
howev
treatment
requir
mani
case
use
invas
administr
method
intraven
subcutan
inject
molecul
interest
reach
target
region
moreov
solubl
purifi
protein
therapeut
compound
frequent
show
low
stabil
andor
poor
effici
organ
forc
repeat
administr
subsequ
increas
amount
need
pharmaceut
frequent
deriv
increas
toxic
cost
treatment
case
recombin
therapeut
protein
produc
microbi
host
biosafeti
concern
rais
mainli
due
possibl
remnant
pyrogen
inflammatori
contamin
trigger
undesir
immunogen
respons
given
need
develop
altern
rout
administr
well
safeti
deliveri
platform
lactic
acid
bacteria
lab
appear
appeal
option
product
deliveri
therapeut
molecul
antigen
interest
heterogen
group
gramposit
bacteria
contrast
gramneg
bacteria
e
coli
contain
lipopolysaccarid
lp
attach
cell
membran
absenc
endotoxin
avoid
gener
anaphylact
shock
lab
administ
human
regard
note
lab
long
histori
safe
use
human
use
centuri
food
product
preserv
context
strain
also
long
record
use
probiot
bacteria
produc
metabolit
macromolecul
abl
maintain
promot
human
health
lab
classifi
food
grade
microorgan
gener
recogn
safe
gra
organ
us
food
drug
administr
fda
fulfil
criteria
qualifi
presumpt
safeti
qp
accord
european
food
safeti
author
efsa
besid
import
stress
exhaust
work
done
develop
differ
tool
recombin
protein
product
use
lab
cell
factori
develop
tool
made
possibl
develop
lab
abl
secret
protein
interest
extracellular
environ
becom
key
aspect
evalu
potenti
bacteria
mucos
target
therapeut
molecul
tabl
altern
approach
base
protein
display
anchor
bacteria
cell
wall
also
test
system
even
effect
secret
protein
term
protein
express
level
give
higher
protect
protein
front
degrad
denatur
agent
tabl
consequ
microorgan
use
oral
intranas
vagin
administr
protein
deliveri
purpos
minim
potenti
side
effect
associ
classic
parenter
subcutan
administr
protein
simultan
reduc
dose
need
although
lab
includ
microorgan
differ
genu
leuconostoc
lactococcu
lactobacillu
pedicoccu
streptococcu
lactococcu
lacti
wide
use
consid
clone
product
recombin
protein
l
lacti
deepli
character
first
one
whose
genom
fulli
sequenc
addit
express
system
easi
manipul
mani
clone
express
system
avail
wide
use
protein
express
system
l
lacti
nice
nisin
control
express
system
base
control
strong
nisin
induc
promot
pnisa
sever
advantag
express
gene
interest
tightli
regul
high
express
level
achiev
use
foodgrad
molecul
nisin
induc
although
sever
protein
biotechnolog
biomed
interest
produc
l
lacti
use
induc
plasmid
prove
experiment
model
clinic
trial
prior
induct
protein
product
requir
case
administr
recombin
bacteria
reason
induc
promot
requir
addit
extern
induc
develop
l
lacti
also
lab
lactobacillu
paracasei
promot
directli
induc
situ
exampl
bacteria
suffer
environment
stress
heatstress
bodi
temperatur
degre
higher
bacteria
optim
growth
temperatur
acidstress
stomach
fluid
enabl
recombin
product
protein
interest
without
need
ad
extern
induc
regard
consid
l
paracasei
respond
stress
synthesis
chaperon
groesl
stressinduc
control
express
sice
system
base
groesl
operon
promot
also
describ
develop
promot
depend
addit
extern
induc
allow
take
import
qualit
leap
toward
use
lab
protein
deliveri
vector
context
aim
take
anoth
step
forward
constitut
promot
also
extens
studi
constitut
promot
make
possibl
get
maintain
express
protein
interest
time
without
need
type
induc
current
wide
explor
possibl
find
import
number
exampl
alreadi
test
protein
deliveri
purpos
special
l
lacti
also
l
paracasei
lactobacillu
casei
lactobacillu
plantarum
bifidobacterium
breve
streptococcu
gordonii
tabl
thu
use
food
grade
microorgan
recombin
protein
cell
factori
deliveri
platform
time
promis
approach
briefli
administr
microorgan
would
also
suppos
signific
decreas
product
cost
drug
live
organ
live
vector
would
abl
autonom
synthes
deliv
prophylact
therapeut
protein
interest
moreov
possibl
simultan
produc
differ
protein
bacteria
altogeth
turn
attract
altern
intraven
administr
nake
recombin
protein
also
classic
deliveri
system
mucos
target
attenu
pathogen
liposom
microparticl
thu
intend
provid
overview
use
genet
modifi
food
grade
organ
engin
attract
vehicl
deliv
function
protein
mucos
tissu
treatment
wide
rang
patholog
git
relat
patholog
well
type
cancer
viral
infect
among
other
fig
inflammatori
bowel
diseas
ibd
idiopath
disord
consist
inflamm
git
believ
abnorm
condit
due
uncontrol
immun
respons
gut
microflora
although
underli
caus
still
unclear
known
environment
genet
factor
import
role
complex
diseas
crohn
diseas
ulcer
coliti
includ
gener
ibd
definit
patient
suffer
chronic
diseas
usual
requir
lifelong
costli
treatment
sever
sideeffect
moreov
mani
case
therapeut
agent
use
fail
despit
medic
treatment
surgeri
need
sens
use
recombin
microorgan
fulfil
qp
standard
overexpress
molecul
abl
allevi
inflamm
could
attract
altern
treatment
sinc
safe
profil
administr
pathway
would
allow
easi
incorpor
treatment
patient
routin
improv
comfort
strategi
propos
use
protein
lowcalcium
v
antigen
lcrv
nanobodi
trefoil
factor
tff
catalas
use
l
lacti
microbi
deliveri
vector
tabl
protein
success
produc
l
lacti
platform
amelior
upon
oral
administr
inflammatori
respons
ibd
anim
model
noteworthi
success
approach
relat
deliveri
therapeut
agent
mucosa
level
clear
exampl
provid
oral
administ
l
lacti
secret
nanobodi
nanobodi
secret
platform
efficaci
similar
observ
establish
therapi
infliximab
remicad
base
intraven
infus
howev
contrari
occur
system
infus
oral
administr
l
lacti
strain
secret
cost
effect
lack
advers
effect
lab
potenti
ibd
treatment
share
object
reduc
gut
inflamm
nevertheless
depend
recombin
protein
deliv
affect
pathway
differ
thu
nanobodi
would
reduc
inflamm
neutral
action
proinflammatori
cytokin
express
regulatori
cytokin
would
decreas
inflamm
thank
antinflammatori
activ
use
enzym
catalas
would
act
inflammatori
respons
deriv
presenc
reactiv
oxygen
speci
ro
approach
probabl
extens
studi
deliveri
produc
l
lacti
fact
l
lacti
secret
submit
clinic
trial
treatment
crohn
diseas
clinicaltrialsgov
identifi
nevertheless
despit
promis
result
observ
mice
clinic
trial
reveal
mention
approach
ineffici
clinicaltrialsgov
identifi
failur
thought
consequ
low
final
concentr
git
regard
recent
propos
use
pleiotrop
cytokin
order
get
broader
respons
due
immunosuppress
role
well
capac
induc
express
besid
elafin
endogen
proteas
inhibitor
also
oral
administ
use
l
lacti
l
casei
deliveri
vector
observ
restor
colon
homeostasi
mice
elastin
diminish
patient
ibd
pleiotrop
antiinflammatori
role
healthi
human
gut
recent
two
antiinflammatori
molecul
name
secretori
leukocyt
proteas
inhibitor
slpi
enzym
secret
l
lacti
shown
abil
notabl
reduc
intestin
inflamm
mice
model
use
local
display
mice
gut
therapeut
protein
lactobacillu
gasseri
l
casei
express
superoxid
dismutas
sod
happen
catalas
sod
action
neutral
ro
speci
deriv
inflammatori
effect
articl
also
publish
explor
potenti
foodgrad
bacteria
treatment
diabet
tabl
context
ng
collabor
prove
l
lacti
abl
secret
insulin
analog
vitro
promot
expect
biolog
effect
target
adipocyt
year
later
agarw
et
al
describ
success
vivo
assay
rat
base
oral
deliveri
glucagon
like
use
l
lacti
deliveri
platform
briefli
emerg
promis
therapeut
peptid
type
diabet
treatment
compound
synthes
git
mainten
glucos
homeostasi
administ
inject
necessari
one
administr
least
week
interestingli
agarw
et
al
observ
recombin
l
lacti
secret
oral
administ
rat
reduct
blood
glucos
level
import
increas
insulin
take
place
nowaday
wide
accept
current
treatment
base
insulin
replac
type
diabet
import
weak
aspect
one
hand
autoimmun
respons
impair
pancrea
inhibit
hand
insulin
inject
prevent
import
associ
complic
diabet
therefor
differ
therapeut
approach
base
immunotherapi
also
explor
use
antigenbas
immunotherapi
promis
autoimmun
diseas
aminoacid
peptid
deriv
human
demonstr
conveni
altern
modul
immunolog
attack
mous
peptid
success
oral
administ
use
recombin
l
lacti
deliveri
carrier
clear
effect
improv
glucos
toler
reduct
insulin
hyperglycemia
addit
anoth
studi
recent
publish
describ
administr
l
lacti
strain
deliv
antigen
proinsulin
glutam
acid
decarboxylas
combin
appeal
method
improv
induct
antigenspecif
toler
treatment
type
diabet
anoth
studi
recent
follow
oral
administr
l
lacti
secret
two
major
autoantigen
type
diabet
name
glutam
acid
decarboxylas
tyrosin
phosphataselik
protein
mous
model
studi
modifi
version
success
use
combin
human
cytokin
cancer
huge
relev
human
health
due
grow
incid
develop
countri
strategi
effect
cancer
treatment
studi
countless
use
lab
recent
appear
field
cancer
develop
progress
broadli
relat
chronic
inflamm
process
produc
extern
factor
infect
radiat
unbalanc
diet
obes
tobacco
exposur
environment
pollut
thu
principl
strategi
aim
treat
chronic
inflamm
could
produc
also
posit
outcom
cancer
occurr
regard
use
lab
organ
colorect
cancer
prevent
explor
use
mainli
colorect
cancer
murin
model
exampl
strain
use
purpos
bifidobacterium
lacti
l
casei
strain
shirota
b
longum
lactobacillu
acidophilu
delvo
pro
lactobacillu
rhamnosu
gg
propionibacterium
freudenreichii
mani
other
render
similar
result
show
signific
decreas
cancer
develop
import
note
although
signific
number
lab
show
promis
vitro
anim
model
conclus
studi
carri
human
hand
interest
studi
regard
biodistribut
microbi
vector
mice
model
illustr
capac
food
grade
speci
reach
solid
tumor
abl
accumul
prolifer
intraven
administr
behavior
relat
hypox
environ
exhibit
tumor
atmospher
anaerob
bacteria
select
grow
capac
exploit
b
longum
propos
antibreast
cancer
strategi
base
recombin
product
cytosin
deaminas
solid
tumor
intraven
administr
microbi
vector
enzym
combin
administr
would
result
local
high
concentr
reaction
product
anoth
exampl
use
bifidobacterium
adolescenti
express
recombin
endostatin
show
safe
vector
abl
select
inhibit
angiogenesi
tumor
growth
tumor
mice
model
intraven
administr
studi
reinforc
capabl
microorgan
genera
classifi
accord
qp
standard
potenti
drug
deliveri
system
cancer
treatment
protein
secret
live
vector
stabl
nake
solubl
protein
intraven
administ
howev
previous
mention
intraven
inject
lab
import
advers
effect
thu
deliveri
live
vector
mucos
level
would
much
appropri
context
potenti
use
oral
administ
drug
deliveri
vector
natur
select
solid
tumor
also
explor
tabl
recombin
b
breve
oral
administ
mice
abl
effect
transloc
git
colon
solid
tumor
level
intraven
administ
one
interestingli
cross
git
recombin
b
breve
involv
increas
permeabl
git
epithelia
promot
cross
potenti
pathogen
bacteria
present
regular
gut
flora
besid
lab
also
oral
administ
take
advantag
natur
nich
bodi
develop
prophylact
strategi
colon
cancer
without
need
git
transloc
sens
recombin
l
lacti
produc
catalas
shown
protect
effect
chemic
induc
colon
cancer
mice
model
tumor
cell
character
increas
product
ro
hydrogen
peroxid
activ
particip
enhanc
tumour
invas
prolifer
thu
administr
l
lacti
produc
catalas
enzym
antioxid
activ
decreas
level
consequ
reduc
colon
damag
inflamm
interestingli
sinc
oxid
stress
associ
increas
ro
level
also
characterist
gastrointestin
patholog
approach
develop
studi
use
also
therapi
treatment
ibd
recent
articl
publish
use
administr
l
lacti
express
human
papillomaviru
oncoprotein
treatment
cervic
cancer
one
articl
protein
produc
secret
sice
plasmid
administr
mice
tumour
result
show
administr
recombin
bacteria
provok
slightli
diminut
tumour
volum
antigenspecif
immun
respons
studi
foodgrad
bacteria
administ
mice
via
intranas
express
anchor
surfac
one
case
protein
combin
administr
induc
tumour
suppress
mice
second
approach
recombin
lactococci
test
simultan
deliveri
protein
murin
dna
observ
new
strategi
combin
deliveri
therapeut
molecul
antigen
high
potenti
final
protein
effect
also
investig
use
l
casei
mucos
deliveri
vector
mice
histor
vaccin
base
attenu
pathogen
microorgan
howev
approach
three
import
drawback
difficulti
construct
stabl
attenu
mutant
b
presenc
residu
virul
attenu
pathogen
c
risk
genet
reassort
vaccin
strain
wild
type
besid
although
pure
antigen
also
use
vaccin
purpos
molecul
low
nonexist
immun
respons
especi
rapid
degrad
poor
adsorpt
vivo
thu
aim
find
altern
strategi
nonpathogen
lab
also
explor
mucos
vaccin
mani
approach
propos
order
produc
present
differ
antigen
develop
l
lacti
also
work
use
lab
lactobacillu
zeae
lactobacillu
jensenii
l
plantarum
l
acidophilu
l
casei
streptococcu
gordinii
bacillu
subtili
tabl
note
sever
lactobacillu
speci
exploit
field
abl
attach
colonis
gastrointestin
mucosa
acidresist
biletoler
besid
presenc
bacteria
may
natur
inhibit
pathogen
colon
pathogen
microorgan
helicobact
pylori
howev
although
lactobacillu
seem
one
best
candid
immun
purpos
protein
express
level
achiev
still
lower
obtain
l
lacti
sinc
low
protein
yield
induc
immun
respons
strong
enough
trigger
protect
infect
agent
optim
antigen
present
requir
possibl
sudden
high
concentr
antigen
obtain
induc
approach
nevertheless
given
common
find
either
insolubl
toxic
recombin
protein
overexpress
constitut
plasmid
good
altern
use
constitut
plasmid
much
safer
approach
necessari
add
extern
induc
get
desir
amount
protein
use
constitut
plasmid
exemplifi
express
sspa
sspb
antigen
gordonii
major
colon
oral
hard
soft
tissu
cell
surfac
l
lacti
use
promot
antigen
success
express
anchor
cell
wall
vitro
abil
adher
gordonii
surfac
proven
anoth
exampl
slpa
constitut
promot
base
slayer
protein
strong
express
signal
slayer
proven
secret
use
l
lacti
l
brevi
l
plantarum
l
gasseri
l
casei
merozoit
surfac
protein
plasmodium
falciparum
use
l
lacti
interestingli
last
studi
prove
potenti
recombin
l
lacti
effect
oral
vaccin
altern
malaria
vivo
studi
antigen
show
capac
confer
protect
vaccin
anim
furthermor
combin
antigen
adjuv
molecul
studi
also
aim
achiev
increas
effici
vaccin
exampl
coexpress
flagellin
flic
salmonella
enterica
l
acidophilu
result
show
gag
antigen
flic
coexpress
promot
gagspecif
igaproduc
cell
local
mucosa
anoth
studi
report
aim
develop
vaccin
chicken
anemia
viru
cav
antigen
produc
e
coli
fuse
bind
domain
acma
major
autolysin
l
lacti
cell
wall
ntermin
aim
enhanc
lactobacillu
immun
abil
case
author
observ
fusion
protein
remain
cell
surfac
least
day
oral
administr
induc
moder
immun
respons
chicken
bifidobacterium
anoth
appeal
foodgrad
vector
abund
human
gut
well
recognis
probiot
abil
activ
cellmedi
immun
respons
without
antigen
present
biletoler
regul
promot
base
upstream
sequenc
bet
bileinduc
transport
gene
recent
develop
order
control
gene
express
specif
intestin
tract
howev
note
bifidobacterium
strict
anaerob
metabol
make
harder
experiment
part
ibd
diabet
cancer
diseas
target
use
food
grade
bacteria
among
interest
exampl
found
control
microbi
infect
tabl
regard
microbi
infect
neutral
antibodi
fragment
express
l
paracasei
l
acidphilu
shown
abl
provid
protect
bacillu
anthraci
l
paracasei
rotaviru
mice
studi
open
possibl
gener
altern
lactobacilli
produc
antibodi
infecti
diseas
affect
git
besid
import
note
lab
organ
classifi
qp
efsa
use
mucos
deliveri
vector
treat
human
diseas
also
anim
diseas
exampl
lab
use
combat
leishmaniasi
moreov
lactobacilli
also
use
design
live
vaccin
combat
wide
rang
diseas
pancreat
necrosi
viru
ipnv
pathogen
infect
wild
cultur
salmonid
highli
pathogen
avian
influenza
hpai
porcin
epidem
diarrhea
viru
pedv
studi
combin
bacteri
effect
express
antigen
either
food
hypersensit
aeroallergen
administr
l
lacti
display
recombin
allergen
intracellularli
extracellular
space
cell
wallanchor
show
capac
modul
specif
antibodi
respons
case
allergen
ara
h
peanut
allerg
der
allergen
dust
mite
allergi
second
studi
author
also
observ
diminut
cellular
infiltr
inflammatori
respons
demonstr
obes
gut
microbiota
composit
strongli
correl
addit
lab
lactobacillu
bifidobacterium
abl
improv
obes
murin
model
human
context
obes
also
target
mice
model
deliveri
recombin
leptin
use
lab
leptin
hormon
crucial
role
bodi
weight
control
case
capabl
protein
carri
action
improv
intranas
administr
engin
l
lacti
secret
hormon
observ
signific
loss
bodi
weight
well
reduct
food
intak
treat
anim
anoth
exampl
administr
cytokinessecret
lab
prophylaxi
therapi
deliveri
inflammatori
bowel
diseas
asthma
coupl
exampl
final
necessari
stress
although
applic
refer
revis
envisag
use
lab
also
eukaryot
express
system
safe
profil
found
literatur
possibl
would
result
interest
case
therapeut
protein
requir
complex
posttransl
modif
becam
fulli
function
regard
prokaryot
cell
factori
would
lack
machineri
perform
requir
process
recombin
protein
nice
exampl
found
recombin
saccharomyc
cerevisia
yeast
propos
vehicl
secret
protein
peptid
therapeut
effect
gut
sens
oral
recombin
cerevisia
display
salmon
recombin
calcitonin
yeast
surfac
prompt
decreas
calcium
level
hypercalcem
rat
oral
administr
previou
section
focus
attent
posit
effect
lab
live
vector
protein
deliveri
howev
import
stress
lab
genet
modifi
organ
gmo
gmo
wide
accept
well
stablish
food
industri
howev
import
regulatori
concern
need
address
use
therapeut
vechicl
specif
lab
base
express
system
carri
antibiot
resist
gene
select
marker
describ
live
vector
could
transfer
antibiot
resist
intestin
microbiota
although
realli
rare
event
report
field
import
issu
consid
applic
lab
live
vector
open
broad
interest
field
possibl
regulatori
measur
consid
ensur
safeti
use
strain
altern
innov
select
marker
alreadi
develop
success
test
posit
evalu
sever
health
author
howev
altern
safe
select
marker
need
explor
final
ensur
real
possibl
use
strain
problem
list
besid
note
advers
effect
lab
report
indic
despit
posit
therapeut
effect
microorgan
low
number
advers
effect
regist
complet
safe
inform
contextu
sinc
advers
effect
observ
high
risk
group
critic
ill
andor
immunecompromis
patient
critic
sick
infant
postop
hospit
patient
sepsi
fungemia
gi
ischemia
main
harm
effect
lab
describ
briefli
vulner
popul
lab
could
interfer
microflora
give
rise
opportunist
infect
final
bacterimia
fungimia
medic
complic
addit
strong
evid
prove
lab
use
probiot
antiinflammatori
effect
howev
mani
report
also
describ
proinflammatori
effect
caus
group
bacteria
mean
probiot
effect
lab
strain
depend
factor
consid
choic
host
strain
therapeut
applic
gener
term
one
conclud
safeti
lab
wide
support
long
tradit
use
microb
safeti
record
lead
us
conclud
ratio
prevent
treatment
multipl
diseas
state
overal
realli
high
studi
report
advers
effect
scarc
nonetheless
risk
benefit
care
consid
situat
especi
healthcompromis
patient
besid
consid
advers
event
poorli
document
accur
safeti
report
includ
pathogen
infect
virul
toxic
would
help
scientif
commun
take
decis
solid
conclus
irrupt
nanotechnolog
innov
approach
allow
develop
altern
classic
medicin
aim
overcom
inher
limit
regard
exploit
lab
recombin
probiot
express
protein
interest
strongli
burst
promis
altern
treatment
wide
rang
diseas
mucos
needlefre
administr
therapeut
molecul
interest
give
ad
valu
lab
besid
shown
applic
recombin
probiot
bacteria
via
intranas
oral
genit
would
dual
effect
direct
effect
design
treatment
specif
diseas
express
recombin
protein
combin
indirect
gener
effect
safe
bacteria
health
addit
administr
live
deliveri
vector
easier
rel
inexpens
compar
inject
treatment
largescal
product
afford
interestingli
use
lab
success
test
wide
rang
medic
applic
mainli
use
anim
model
treatment
autoimmun
diseas
intens
investig
foodgrad
bacteria
also
propos
excel
candid
vaccin
still
lot
done
long
way
reach
market
articl
publish
let
us
suggest
lab
promis
deliveri
vector
vast
rang
biomed
applic
next
step
detail
studi
factor
could
becom
import
bottleneck
futur
implement
lab
effect
live
vector
deliv
protein
interest
situ
import
safeti
regulatori
issu
still
need
address
depth
signific
step
alreadi
done
context
small
trial
use
auxotroph
strain
posit
evalu
treatment
patient
chron
diseas
aspect
extens
studi
real
cost
effici
still
outstand
question
need
answer
